|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-7-30
|
|
pubmed:abstractText |
The third-generation aromatase inhibitors reduce circulating estrogen levels in postmenopausal women and are well tolerated orally for breast cancer. Their role in the management of advanced breast cancer has already been recognized. This article reviews the evidence for their role in the adjuvant treatment of early-stage disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1526-2359
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
217-21
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15284712-Androstadienes,
pubmed-meshheading:15284712-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15284712-Aromatase Inhibitors,
pubmed-meshheading:15284712-Breast Neoplasms,
pubmed-meshheading:15284712-Chemotherapy, Adjuvant,
pubmed-meshheading:15284712-Endometrial Neoplasms,
pubmed-meshheading:15284712-Female,
pubmed-meshheading:15284712-Hot Flashes,
pubmed-meshheading:15284712-Humans,
pubmed-meshheading:15284712-Multicenter Studies as Topic,
pubmed-meshheading:15284712-Nitriles,
pubmed-meshheading:15284712-Research Design,
pubmed-meshheading:15284712-Stroke,
pubmed-meshheading:15284712-Tamoxifen,
pubmed-meshheading:15284712-Thromboembolism,
pubmed-meshheading:15284712-Treatment Outcome,
pubmed-meshheading:15284712-Triazoles,
pubmed-meshheading:15284712-Uterine Hemorrhage,
pubmed-meshheading:15284712-Vaginal Discharge
|
|
pubmed:articleTitle |
Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial.
|
|
pubmed:affiliation |
University College London, The Portland Hospital, London, UK. michael@mbaum.freeserve.co.uk
|
|
pubmed:publicationType |
Journal Article,
Review
|
